Adam Garsa

Dr. Adam Garsa

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Practical Radiation Oncology
Verified
Journal Article
Open access
AGAdam Garsa
Adam Garsa
JJJulie K. Jang
Julie K. Jang
SBSangita Baxi
Sangita Baxi
CCChristine Chen
Christine Chen
OAOlamigoke Akinniranye
Olamigoke Akinniranye
SHSusanne Hempel
Susanne Hempel
This evidence report synthesizes the available evidence on radiation therapy for brain metastases. The literature search included PubMed, EMBASE, Web of Science, Scopus, CINAHL, clinicaltrials.gov, and published guidelines in July 2020; independently submitted data, expert consultation, and contacting authors. Included studies were randomized controlled trials (RCTs) and large observational studies (for safety assessments), evaluating whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) alone or in combination, as initial or postoperative treatment, with or without systemic therapy for adults with brain metastases due to lung cancer, breast cancer, or melanoma. Ninety-seven studies reported in 189 publications were identified, but the number of analyses was limited owing to different intervention and comparator combinations as well as insufficient reporting of outcome data. Risk of bias varied, and 25 trials were terminated early, predominantly owing to poor accrual. The combination of SRS plus WBRT compared with SRS alone or WBRT alone showed no statistically significant difference in overall survival (hazard ratio [HR], 1.09; 95% confidence interval [CI], 0.69%-1.73%; 4 RCTs) or death owing to brain metastases (relative risk [RR], 0.93; 95% CI, 0.48%-1.81%; 3 RCTs). Radiation therapy after surgery did not improve overall survival compared with surgery alone (HR, 0.98; 95% CI, 0.76%-1.26%; 5 RCTs). Data for quality of life, functional status, and cognitive effects were insufficient to determine effects of WBRT, SRS, or postsurgery interventions. We did not find systematic differences across interventions in serious adverse events, number of adverse events, radiation necrosis, fatigue, or seizures. WBRT plus systemic therapy (RR 1.44; 95% CI, 1.03%-2.00%; 14 studies) was associated with increased risks for vomiting compared with WBRT alone. Despite the substantial research literature on radiation therapy, comparative effectiveness information is limited. There is a need for more data on patient-relevant outcomes such as quality of life, functional status, and cognitive effects.

1 October 2014 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
AGAdam Garsa
Adam Garsa
SBShahed N. Badiyan
Shahed N. Badiyan
TDTodd DeWees
Todd DeWees
JSJoseph R. Simpson
Joseph R. Simpson
JHJiayi Huang
Jiayi Huang
CRClifford G. Robinson
Clifford G. Robinson

20 June 2025 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
AGAdam Garsa
Adam Garsa
CBCourtney R. Buckey
Courtney R. Buckey
BDBrian J. Davis
Brian J. Davis
LFLaura Freedman
Laura Freedman
SGSebastien A.A. Gros
Sebastien A.A. Gros
NSNaomi R. Schechter
Naomi R. Schechter
Objectives: This practice parameter was revised collaboratively by the American College of Radiology (ACR), and American Radium Society (ARS). Image-guided radiation therapy (IGRT) uses various imaging modalities to maximize the accuracy and precision of radiation treatment delivery. Methods: This practice parameter was developed according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters–Radiation Oncology of the ACR Commission on Radiation Oncology in collaboration with the ARS. Results: This practice parameter for IGRT addresses qualifications and responsibilities of personnel, clinical IGRT implementation, documentation, quality control and improvement, safety, and patient education. Since the publication of the ACR–ASTRO Practice Parameter in 2019, there is now more clarity as to what criteria and parameters need to be documented in the medical record, a better appreciation of the large amount of imaging data, how to interpret such data, as well as the complex interactions of multiple systems in the implementation of IGRT. Conclusions: This practice parameter assists practitioners in the clinical use of IGRT. IGRT should complement and be used in combination with other quality assurance processes. IGRT is a rapidly evolving field, and practitioners should have a thorough understanding of its strengths and potential limitations.

3 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Hualin ZhangHualin Zhang
Hualin Zhang
NDNguyen Phuong Dang
Nguyen Phuong Dang
JYJason C. Ye
Jason C. Ye
AGAdam Garsa
Adam Garsa
AMAram S. Modrek
Aram S. Modrek
ECEric L. Chang
Eric L. Chang
Purpose: Tile-based radiation therapy (TBRT) delivers adjuvant radiation to brain tumor beds using evenly spaced cesium-131 (Cs-131) sources in collagen tiles. This study evaluated TBRT as spatially fractionated radiation therapy (SFRT) across tumor sizes and source counts. Methods and Materials: Dose distributions were generated from postoperative CT scans for 18 patients treated with TBRT, using 10–32 implanted Cs-131 sources per case (median, 20). The resection cavity (RC) was contoured on CT with registered postoperative T1-weighted MRI guidance. CTV_5mm was defined as the RC plus a 5 mm expansion excluding skull and surgical tract, and CTV_5mm_Eval as CTV_5mm minus the RC. Both volumes were analyzed using SFRT dose metrics from the Radiosurgery Society SFRT/Flash working group white paper, and planar high-dose core number density (HCND_A) was used to characterize TBRT spatial fractionation. Results: The mean dose indices of D5 (dose covering 5% of the target volume), D10, D50, D90, D95 and D100 were 175.8 ± 43.3, 148.8 ± 35.1, 86.7 ± 18.5, 56.1 ± 10.5, 50.2 ± 9.0 and 33.4 ± 7.2 Gy for the CTV_5mm_Eval, respectively. The heterogeneity indices, represented by the ratio of D5/D95 and D10/D90, were 3.5 ± 0.6 and 2.7 ± 0.4, respectively, which were in the range of the linac-based Lattice therapy. HCND_A was a constant, TBRT delivered one high dose core for every 1 cm2 of tumor bed. All dose metrics in both the CTV_5mm and CTV_5mm_Eval were largely consistent across all plans. Conclusions: TBRT produced heterogeneous dose distributions comparable to conventional SFRT. A 60 Gy TBRT nominal prescription dose approximated the SFRT D90, or valley dose of the 5 mm expansion target volume, suggesting TBRT may provide an SFRT platform for tile-accessible cancers.

1 June 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
PDF file
HVHarish N. Vasudevan
Harish N. Vasudevan
DRDavid R. Raleigh
David R. Raleigh
JJJulian Johnson
Julian Johnson
AGAdam Garsa
Adam Garsa
PTPhilip V. Theodosopoulos
Philip V. Theodosopoulos
SBSteve Braunstein
Steve Braunstein